Endometrial Cancer
Worse endometrial cancer survival predicted by higher paclitaxel AUC
Published in OBGYN and Reproduction Week, August 28th, 2006
According to a recently published article, scientists in the United States conducted a study "to examine determinants of paclitaxel disposition and the association between paclitaxel exposure and toxicity or survival in patients with advanced stage or recurrent endometrial cancer treated with doxorubicin plus paclitaxel. A limited sampling scheme was used to examine the population pharmacokinetics of paclitaxel in 160 patients from one arm of a randomized Phase III trial of doxorubicin plus paclitaxel or cisplatin."
"Four plasma samples per patient were...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
More Articles from OBGYN and Reproduction Week
- Cervical Cancer
Cytomorphologic features related to increased false-positive Pap tests in women were identified - Cervical Cancer
Human papillomavirus 16 and 18 viral load are associated with more severe cervical lesions - Obstetrics
Leptin may be a marker of hyperemesis gravidarum during pregnancy - Obstetrics
Risk of miscarriage is not increased by aspirin use during pregnancy - Obstetrics
Risk of preeclampsia is increased in women with adult weight gain, prepregnancy overweight - Anesthesia
Hysterosalpingography with paracervical anesthetic block produces less discomfort - More from this issue of OBGYN and Reproduction Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
